N-substituted thiourea derivatives based aminoalcohols: Discovery of potent cholinesterase inhibitors as new therapeutic approach In Alzheimer's disease

dc.contributor.authorSujayev, Afsun
dc.contributor.authorTaslimi, Parham
dc.contributor.authorJavadzade, Tahir
dc.contributor.authorAslanov, Said
dc.contributor.authorBursal, Ercan
dc.contributor.authorTaskin-Tok, Tugba
dc.contributor.authorGulcin, Ilhami
dc.date.accessioned2026-07-13T12:18:10Z
dc.date.issued2025
dc.departmentMuş Alparslan Üniversitesi
dc.description.abstractA novel series of aminoalcohol-based N-substituted thiourea derivatives (T1-T5) were synthesized and systematically evaluated as potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. The structures of the synthesized compounds were elucidated using 1H and 13C NMR spectroscopies. In vitro enzyme inhibition studies revealed that all derivatives exhibited significant cholinesterase inhibitory effect at the nanomolar level. Among these, compound T3, bearing an electron-donating isopropylamino substituent, emerged as the most potent double inhibitor, exhibiting K-i values of 43.57 +/- 5.52 nM for AChE and 90.03 +/- 8.33 nM for BChE. To rationalize the experimental findings, structure-based molecular docking studies (in silico applications) were performed against human AChE and BChE. The docking results showed strong agreement with in vitro data; compound T3 exhibited optimal binding affinities (-9.6 Kcal/mol for AChE and-9.0 Kcal/mol for BChE) and stable interaction patterns involving both catalytic and peripheral site residues. Structure-activity relationship analysis showed that electron-donating N-substituents and the flexible aminoalcohol-thiourea skeleton played a significant role in enhancing the inhibitory potential. Overall, the combined experimental and computational results identify compound T3 as a promising dual AChE/BChE inhibitor and highlight aminoalcohol-based N-substituted thioureas as a valuable skeleton for further optimization in Alzheimer's disease-related drug discovery.
dc.description.sponsorshipAzerbaijan Science Foundation [S/N AEF-BQM-BRFTF-4-2024-5 (53) -06/06/4-M-06] -- A.S. acknowledges the Azerbaijan Science Foundation, S/N AEF-BQM-BRFTF-4-2024-5 (53) -06/06/4-M-06.
dc.identifier.doi10.1016/j.lddd.2026.100294
dc.identifier.issn1570-1808
dc.identifier.issn1875-628X
dc.identifier.issue12
dc.identifier.scopus2-s2.0-105029300750
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.lddd.2026.100294
dc.identifier.urihttps://hdl.handle.net/20.500.12639/8848
dc.identifier.volume22
dc.identifier.wosWOS:001728736100001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherKeai Publishing Ltd
dc.relation.ispartofLetters in Drug Design & Discovery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250701
dc.subjectAcetylcholinesterase
dc.subjectButrylcholinesterase
dc.subjectAminoalcohols
dc.subjectN-Substituted Tiourea
dc.subjectIn Silico Applications
dc.titleN-substituted thiourea derivatives based aminoalcohols: Discovery of potent cholinesterase inhibitors as new therapeutic approach In Alzheimer's disease
dc.typeArticle

Dosyalar